Reference (Year) | EI (Country) | FD (MM) (No. of lost) | Group | No. of patients (M/F) | Age, years | PHB, g/dl | Pathology Aa/Sc/Lc/Ot | TS I/II/II/IV | OT Pr/Pn | Quality score |
---|---|---|---|---|---|---|---|---|---|---|
Tartter [2] (1984) | 1966–1980 (USA) | 24 | Transfused | 92 (−) | – | – | – | All stage I | – | 4 |
(−) | Non-transfused | 73 (−) | – | – | – | All stage I | – | |||
Hyman [3] (1985) | 1971–1979 (USA) | – | Transfused | 33 (25/8) | 59.5 ± 8 | – | 9/21/3/0 | 27/6/0/0 | 22/11 | 5 |
(−) | Non-transfused | 72 (58/14) | 62.4 ± 7.1 | – | 20/38/11/3 | 67/5/0/0 | 55/17 | |||
Pastorino [6] (1986) | 1974–1979 (Italy) | – | Transfused | 157 (147/10) | > 60, n = 75 | – | 53/79/25/0 | All stage I | 113/44 | 6 |
(−) | Non-transfused | 126 (117/9) | > 60, n = 64 | – | 49/59/18 | All stage I | 105/21 | |||
Keller [7] (1988) | 1974–1981 (USA) | (−) | Transfused | 144 (91/53) | ≥ 65.1, n = 73 | – | – | 119/25/0/0 | 127/17 | 5 |
– | Non-transfused | 208 (149/59) | ≥ 65.1, n = 65 | – | – | 186/22/0/0 | 201/7 | |||
Little [5] (1990) | 1977–1986 (USA) | 47 | Transfused | 58 (32/26) | 61.3 ± 8.8 | – | 26/25/7/0 | All stage I | 48/10 | 5 |
(0) | Non-transfused | 59 (28/31) | 60.1 ± 9.6 | – | 37/16/6/0 | All stage I | 51/8 | |||
Pena [8] (1992) | 1980–1984 (USA) | – | Transfused | 30 (24/6) | 66.1 ± 7.6 | 12.8 ± 1.9 | 10/15/3/2 | 23/7/0/0 | 22/8 | 6 |
(−) | Non-transfused | 97 (78/19) | 62.0 ± 8.0 | 14.2 ± 1.3 | 41/41/12/3 | 75/22/0/0 | 71/26 | |||
Piantadosi [13] (1994) | 1974–1981 (USA) | 43.2 | Transfused | 169 (−) | – | – | – | – | – | 6 |
(−) | Non-transfused | 161 (−) | – | – | – | – | – | |||
Rainio [9] (1996) | 1978–1980 (Finland) | – | Transfused | 95 (88/7) | – | – | – | 60/8/27/0 | – | 5 |
(−) | Non-transfused | 113 (102/11) | – | – | – | 83/10/20 | – | |||
Nosotti [14] (2003) | 1995–2000 (Italy) | 34 | Transfused | 69 (52/17) | 65.6 ± 9.4 | 12.5 ± 1.2 | 39/28/2/0 | All stage I | – | 6 |
(38) | Non-transfused | 212 (153/59) | 64.5 ± 9.5 | 13.3 ± 3.1 | 139/66/7/0 | All stage I | – | |||
Rzyman [15] (2003) | 1993–1997 (Poland) | 46 | Transfused | 185 (155/30) | 59.5 | ≤12, 25% | 51/113/19/2 | 62/41/80/2 | 113/72 | 4 |
(0) | Non-transfused | 163 (125/38) | 60.3 | ≤12, 12% | 43/108/9/3 | 85/33/41/4 | 121/42 | |||
Ghosh [16] (2004) | 1996–2003 (UK) | 23.2# | Transfused | 120 (73/47) | 72 | – | 62/58/0/0 | 29/66/27/0 | All Pr | 5 |
(−) | Non-transfused | 209 (99/110) | 69 | – | 83/126/0/0 | 53/85/58/0 | All Pr | |||
Berardi [17] (2005) | 1996–2001 (Italy) | 27 | Transfused | 97 (−) | – | – | – | – | – | 4 |
(−) | Non-transfused | 342 (−) | – | – | – | – | – | |||
Peñalver [18] (2005) | 1969-2000 (Spain) | 208.6# | Transfused | 125 (120/5) | 62.6 ± 9.01 | – | 21/89/15/0 | All stage I | 81/44 | 5 |
(−) | Non-transfused | 731 (688/43) | 61.9 ± 8.95 | – | 199/466/66/0 | All stage I | 584/147 | |||
Chen [19] (2007) | 1993-2002 (China) | – | Transfused | 135 (110/25) | 58.6 ± 11.2 | 13.8 ± 2.1 | 60/55/5/15 | 50/27/58/0 | – | 5 |
(0) | Non-transfused | 145 (117/28) | 59.8 ± 11.1 | 14.2 ± 1.4 | 75/52/5/13 | 74/26/45/0 | – | |||
Thomas [20] (2007) | 1993–2002 (France) | – | Transfused | 139 (−) | – | – | 39/77/17/6 | – | All Pn | 5 |
– | Non-transfused | 228 (−) | – | – | 70/113/25/20 | – | All Pn | |||
Panagopoulos [21] (2008) | 1999–2005 (Greece) | 27.2 | Transfused | 85 (74/11) | 64 ± 9 | 11.5 ± 1.6 | 30/46/7/2 | 33/27/23/2 | 45/40 | 4 |
(0) | Non-transfused | 246 (221/25) | 64 ± 9 | 12.7 ± 1.3 | 85/132/24/5 | 115/65/61/5 | 164/82 | |||
Ng [22] (2012) | 2001–2009 (USA) | 48 | Transfused | 63 (31/32) | 74 | 12.6 | 43/12/6/2 | All stage I | All Pr | 6 |
(0) | Non-transfused | 298 (130/168) | 67 | 13.5 | 187/69/21/21 | All stage I | All Pr | |||
Cata [23] (2013) | 2004–2006 (USA) | 63.6 | Transfused | 60 (31/29) | 66.2 ± 9.4 | 12.08 ± 1.58 | – | 23/16/21/0 | – | 6 |
37 | Non-transfused | 576 (267/309) | 65.1 ± 10.5 | 13.43 ± 1.42 | – | 328/115/131/0 | – |